

10/075,918

- 2 -

Barvian et al.

AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

Claims 1 and 2 (canceled).


RECEIVED
CENTRAL FAX CENTER

DEC 07 2004

Claim 3 (previously presented).

A method for treating breast

carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula III



III

wherein:

R¹, R², and R³ independently are hydrogen, halo, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, NO₂, NR⁴R⁵, CN, or CF₃;

R⁴ and R⁵ independently are (CH₂)_n heterocyclyl, (CH₂)_n heteroaryl, or

R⁴ and R⁵ when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.


10/075,918

- 3 -

Barvian et al.

Claims 4 and 5 (cancelled).**Claim 6 (previously presented).**

A method for treating breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula VI



VI

or a pharmaceutically acceptable salt thereof,

wherein:

R¹, R², and R³ independently are hydrogen, halo, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, NO₂, NR⁴R⁵, CN, or CF₃;

R⁴ and R⁵ independently are (CH₂)_n heterocyclyl, (CH₂)_n heteroaryl, or R⁴ and R⁵ when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; and
n is an integer from 0 to 6.

Claim 7 (previously presented).

A compound selected from the group consisting of:

Isophthalic acid di-(2,1,3-benzothiadiazol-5-yl) methyl ester;

4-Methoxy-isophthalic acid dipyridin-4-ylmethyl ester;

N,N'-Bis-1,3-benzodioxol-5-ylmethyl-4-methoxy-isophthalamide;

10/075,918


- 4 -

Barvian et al.

N-1,3-Benzodioxol-5-ylmethyl-N'-furan-2-ylmethyl-isophthalamide;
 4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester;
 N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;
 N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;
 N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;
 N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;
 4-Amino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;
 4-Acetylamino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;
 N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;
 N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;
 N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-propoxy-isophthalamide;
 N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;
 N1,N3-Bis-2,1,3-benzothiadiazol-5-ylmethyl-4-methoxy-isophthalamide;
 and
 4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester.

Claims 8 to 17 (cancelled).

Claim 18 (previously presented). A compound of Formula III



wherein:

R^1 , R^2 , and R^3 independently are hydrogen, halo, hydroxy, C_1 - C_6 alkyl,
 C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, NO_2 , NR^4R^5 , CN,
 or CF_3 ;

10/075,918

- 5 -

Barvian et al.

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;
 n is an integer from 0 to 6;
or a pharmaceutically acceptable salt thereof.

Claim 19 (new). A pharmaceutical composition, comprising a compound of Claim 18, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

Claim 20 (new). A method for treating breast carcinoma, the method comprising administering to a patient suffering from breast carcinoma an anticancer effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 21 (new). A method for treating rheumatoid arthritis, the method comprising administering to a patient suffering from rheumatoid arthritis a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 22 (new). A method for treating osteoarthritis, the method comprising administering to a patient suffering from osteoarthritis a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 23 (new). A method for treating heart failure, the method comprising administering to a patient suffering from heart failure a

10/075,918

- 6 -

Barvian et al.

therapeutically effective amount of a compound of Claim 18, or a
pharmaceutically acceptable salt thereof.